3 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
Follow Gastrinoma: new trials by email Literature Review of Gastrinoma trials Research Report on Gastrinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs 177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Withdrawn | British Columbia Cancer Agency | 2023-01-15 | 2023-02-21 | |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors dovitinib lactate, pharmacological study, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2014-10-01 | 2017-07-19 | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors octreotide acetate, vatalanib, anti-cytokine therapy - Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma | Phase 2 | Withdrawn | Eastern Cooperative Oncology Group | 2015-10-08 |
Insulinoma (3) · Carcinoma, Islet Cell (2) · Glucagonoma (2) · Somatostatinoma (2) · Vipoma (2) · Carcinoid Tumor (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Neuroendocrine Tumors (1)
Adenocarcinoma (3) · Adenoma (3) · Adenoma, Islet Cell (3) · Carcinoma (3) · Carcinoma, Neuroendocrine (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neuroectodermal Tumors (3)
177Lu-octreotide, DOTA(0)-Tyr(3)- (1) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · Biological Therapy (1) · Octreotide (1) · vatalanib (1)
Academic and Community Cancer Research United (1) · British Columbia Cancer Agency (1) · Eastern Cooperative Oncology Group (1)
Canada (1)
Emily Bergsland (1) · Francois Benard, MD (1) · Kyle Holen, MD (1) · Mary Mulcahy, MD (1)